BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
James M. Ford, M.D.	Associate Professor of Medicine, Pediatrics and Genetics
eRA COMMONS USER NAME FORD.JAMES	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Yale University	B.A.	1984	Biology
Yale University School of Medicine	M.D.	1989	Medicine
Stanford University School of Medicine	Fellow	1994	Medical Oncology
Stanford University	Postdoc	1997	Biological Sciences

Professional Positions

1989-91 Intern and Resident, Internal Medicine, Stanford University Medical Center
1991-94 Clinical Fellow, Medical Oncology, Stanford University Medical Center
1993-97 Research Fellow, Dept. of Biological Sciences, Stanford University (with Prof. Phil Hanawalt)
1998-06 Assistant Professor of Medicine (Oncology) and Genetics, Stanford Univ. Medical School
1999- Director, Stanford Cancer Genetics Program and Clinic
2002- Director, Stanford Medical Oncology Fellowship Training Program
2003-06 Assistant Professor of Pediatrics (by courtesy), Division of Medical Genetics
2006- Associate Professor of Medicine (Oncology), Pediatrics (Medical Genetics) and Genetics (tenured)

Other Experience and Professional Activities

2001-05 ASCO Annual Meeting Human Genetics/Tumor Biology Scientific Program Committee
2002-03 ASCO Working Committee for Clinical Cancer Genetics Workshop
2003- Council Member, California Breast Cancer Research Program (Chair, 2009 – 10)
2003- V Foundation Scientific Review Committee
2005 Chair, AACR Program Committee, DNA Damage and Repair Section
2005 Co-Chair, AACR Annual Meeting Mini-Symposium, “DNA Repair and Genomic Instability”
2006-08 ASCO Education Committee, Tumor Biology Track Leader
2007-08 AACR/NCI/EORTC Annual Meeting Scientific Advisory Board
2002-07 Reviewer, DOD Breast Cancer Research Program
2002-07 Reviewer, Susan G. Komen Breast Cancer Foundation Research Grant Program
2008-11 Chair, Komen Research Grant Review Section, Diagnostic & Prognostic Biomarkers
2006-07 NIH/NCI Molecular Biology PPG Special Emphasis Panel Study Section
2008 NIH/NCI Sub-Committee E – Epidemiology Program Project Grant Study Section
2009 NIH/NCI Sub-Committee I – Career Development Grant Study Section
2003- Editorial Board, *Cancer Research*
2004- Editorial Board, *DNA Repair*
2008- Associate Editor, *PLoS Genetics*
2005- NCCN Guidelines Committees: Colorectal Cancer Screening; Genetics/Familial High Risk Assessment

Honors and Awards

1984 B.A., *Magna Cum Laude*, Yale University
1995 NIH K08 Clinical Investigator Award
1999 Sidney Kimmel Foundation for Cancer Research Scholar Award
1999 Doris Duke Foundation Clinical Scientist Award in Cancer Etiology and Pathogenesis
2000 Burroughs Wellcome Fund New Investigator Award in Toxicological Sciences
2002 V Foundation Translational Research Award
2005 Evelyn Lauder Breast Cancer Research Foundation Scholar
2007 Member, Western Society for Clinical Investigation

Selected peer-reviewed publications (Out of a total of 90)

Ford JM, Prozialeck WC, and Hait WN. Structural features that determine activity for phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. *Mol. Pharmacol.* **35:** 105 - 115 (1989).

Ford JM and Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. *Pharmacol. Rev.* **42:**155 (1990).

Ford JM and Hanawalt PC. Li-Fraumeni syndrome human skin fibroblasts homozygous for p53 mutations are deficient in global nucleotide excision repair, but exhibit normal transcription-coupled repair and UV resistance. *Proc. Natl. Acad. Sci.* **92:** 8876-8880 (1995).

Ford JM and Hanawalt PC. Role of DNA excision repair gene defects in the etiology of cancer. *Current Topics in Microbiology and Immunology* **221**:47-70 (1997).

Ford JM and Hanawalt PC. Expression of wild-type p53 is required for efficient nucleotide excision repair in UV-irradiated human fibroblasts. *Journal of Biological Chemistry* **272:** 28073-28080 (1997).

Hwang BJ, **Ford JM**, Hanawalt PC and Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. *Proc. Natl. Acad. Sci., USA* **96:**424-428 (1999).

Smith ML, **Ford JM**, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng C, Hanawalt PC and Fornace AJ. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. *Molecular and Cellular Biology* **20:** 3705-3714 (2000).

Tang JY, Hwang BJ, **Ford JM**, Hanawalt PC and Chu G. Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. *Molecular Cell* **5:** 737-744 (2000).

Hartman AR and **Ford JM**. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. *Nature Genetics* **32:**180 – 184 (2002).

Adimoolam S and **Ford JM**. p53 and DNA damage inducible expression of the xeroderma pigmentosum group C gene. *Proc. Natl. Acad. Sci. USA.* **99:** 12985-12990 (2002).

Fitch ME, Cross I and **Ford JM**. p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation induced DNA damage. *Carcinogenesis* **24:** 843 – 850 (2003).

Fitch ME, Cross I, Turner S, Adimoolam S, Lin CX, Williams K, **Ford JM**. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. *DNA Repair* **2:** 819 - 826 (2003).

Fitch ME, Nakajima S, Yasui A and **Ford JM**. *In vivo* stimulation of XPC protein binding to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. *J. Biol. Chem.,* **278:** 46906 – 46910 (2003).

Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, **Ford JM** and Plevritis SK. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. *Cancer*, **100:** 479 – 489 (2004).

Brooks-Wilson AR, **Ford J**, Huntsman D, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. *J. Medical Genetics* **41:** 508 – 517 (2004).

Kurian AW, Mills MM, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, **Ford JM**, AR Hartman. Ductal lavage of fluid-yielding and nonfluid-yielding ducts in BRCA1 and 2 mutation carriers and other women at high inherited breast cancer risk. *Cancer Epidemiol Biomarkers Prev* **14:** 1082 - 1089 (2005).

Suriano G, **Ford JM**, Longacre TA, Norton JA, Chun N, Lynch H, Huntsman DG, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. *Clin Cancer Res* **11:** 5401-5409 (2005).

Bomgarden RD, Lupardus PJ, Yee MC, **Ford JM** and Cimprich KA. Opposing roles of UV lesion repair protein XPA and UV bypass polymerase h on ATR checkpoint activation. *EMBO J*. **7:** 2605 – 2614 (2006).

Chen X, Zhang J, Lee J, Lin P, **Ford JM**, Zheng N and Zhou P. A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. *Mol. Cell.* **22:** 489-499 (2006).

Ji H, Kumm J, Zhang M, Farnam K, Salari K, Faham M, **Ford JM**, Davis RW. Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. *Cancer Research* **66:** 7910-7919 (2006).

Ford JM and Whittemore A. Prediction and prevention of hereditary colorectal cancer. *JAMA* **296**:1521-1523 (2006).

Norton JA, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Kurian AW, Chun N and **Ford JM**. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Annals of Surgery* **245:** 873 – 879 (2007).

Kaurah P, **Ford J**, Pharoah P, Fernandez B, Huntsman D. et al. Founder and recurrent *CDH1* mutations in hereditary diffuse gastric cancer families. *JAMA* **297:** 2360 - 2372 (2007).

Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K and **Ford JM**. A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. *Cancer Genetics and Cytogenetics* **179:** 89 – 92 (2007).

Adimoolam S, Sirisawad M, Chen J, Thiemman P, **Ford JM** and Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. **104:** 19482 - 87, *PNAS* (2007).

Kwong A, Wong LP, Chan KYK, Ma ESK, Khoo US and **Ford JM**. Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. *Familial Cancer* **7:** 125-33 (2008).

Staton AD, Kurian AW, Cobb K, Mills MA and **Ford JM**. Risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. *Familial Cancer* **7:** 179-86 (2008).

Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Chun N, Kingham K, **Ford JM** and Longacre TA. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. *American Journal of Surgical Pathology* , **32:** 799 - 809 (2008).

Schiffman JD, Chun N, Fisher PG, Dahl GV, **Ford JM** and Eggerding FA. Identification of a novel p53 gene in-frame deletion in a Li-Fraumeni-Like family. *Pediatric Blood Cancer* **50:** 914 – 916 (2008).

Cisco RM, **Ford JM** and Norton JA. Hereditary Diffuse Gastric Cancer: Implications of genetic testing for screening and prophylactic surgery. *Cancer* **113** (suppl 7): 1850-56 (2008).

Jensen KC, Mariappan R, Putcha GV, Hussain A, Chun N, **Ford JM,** Schrijver I, and Longacre TA. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. *American Journal of Surgical Pathology* **32:** 1029-37 (2008).

Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, **Ford JM**, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP and Koong AC. Gemcitabine chemotherapy and a single fraction of stereotactic body radiation therapy for the treatment of locally advanced pancreas cancer. *Int'l J. Radiation Oncology, Biology, Physics*, **72:** 678-86 (2008).

Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BA, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, and **Ford JM**. *BRCA1* and *BRCA2* mutations and predictive model performance in Asian-Americans. *J. Clin. Onc.* **26:** 4752 - 58 (2008).

Alli E, Sharma VB, Sunderesakumar P and **Ford JM**. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. *Cancer Research* **69:** 2589 – 96 (2009).

Kwong A, Wong LP, Wong HN, Law FBF, Tang YH, Ng EKO, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FCS, Chan S, Ying MWL, Ma ESK and **Ford JM**. A BRCA2 founder mutation and 7 novel deleterious BRCA mutations in Southern Chinese women with breast and ovarian cancer. *Breast Cancer Research and Treatment* Published Online (April 8, 2009).

Hastak K, Alli E and **Ford JM**. Synergistic chemosensitivity of triple-negative breast cancer cell lines to a PARP inhibitor, gemcitabine and cisplatin. Submitted (2009).

Ongoing Research Support

NIH/NCI 1R01 CA108794-01 (Ford, PI) 7/01/04 – 4/30/09

Ubiquitin-Mediated Regulation of DNA Repair.

To study how the ubiquitin-proteasome pathway regulates human nucleotide excision repair factors and activity following DNA damage.

Breast Cancer Research Foundation (Ford, PI) 10/01/05 - 10/01/09

Genetics and Clinical Research in Breast Cancer.

(1). Lovastatin for Breast Cancer Chemoprevention and Biomarker Modification

Clinical trial and translational research using lovastatin for prevention of breast cancer and modification of biomarkers in breast epithelial cells in BRCA1 and BRCA2 carriers.

(2). Targeting DNA Repair Defects in Triple-Negative Breast Cancer

Phase II clinical trial with translational correlative studies of neoadjuvant carboplatin, gemcitabine and the novel PARP inhibitor BSI201 for ER–, PR–, Her2– breast cancer.

Mary Kay Ash Charitable Foundation (Ford, PI) 7/01/07 - 6/30/09

A Novel Approach to Identify Chemoprevention Agents for BRCA1-Associated Malignancies.

To identify new agents that activate DNA repair function to prevent formation of BRCA1 deficient breast cancers by screening a large library of 130,000 compounds for drugs that activate DNA repair using a novel high-throughput approach.

Komen Postdoctoral Fellowship – Basic Research (Ford, PI) 9/01/08 – 9/01/11

BRCA1-mediated Regulation of Oxidative DNA Damage in Breast Cancer (Alli)

Komen Postdoctoral Fellowship – Basic Research (Ford, PI) 9/01/08 – 9/01/11

Genetic Determinants of Chemosensitivity in Triple Negative Breast Cancer Cells (Hastak)

Center for Children's Brain Tumors at LPCH (Ford, PI) 07/01/08 - 06/30/10
Novel Genomic Technology to Classify and Risk Stratify Pediatric Gliomas
Use molecular inversion probes to assess genomic instability in human pediatric gliomas.

Completed Research Support

NIH/NCI R21 CA109190-01 (Ford, PI) 4/01/05 - 4/30/08
Genome-Wide Allelic Imbalances in Colon Cancer

The Susan G. Komen Breast Cancer Foundation POP0503911 (Ford, PI) 5/1/05 - 4/30/08
A Clinic-Based Study of BRCA Mutation Carriage, Differences in
BRCAPRO Scores, and Breast Risk Factors Among Asians and Caucasians.

DOD Idea Award (Ford, PI) 5/07/04 - 5/06/07
Loss of Nucleotide Excision Repair as a Source of Genomic Instability in Breast Cancer

V Foundation Translational Research Grant (Ford, Co-PI) 10/1/02 – 10/1/05
Determinants of Genomic Instability in Women
with BRCA1 Mutations undergoing Comprehensive Breast Cancer Screening.

Technology Transfer Program (Ford, PI) 9/1/00 - 8/29/04
California Cancer Research Program
Program for Applied Cancer Genetics

Clinical Research Scientist Award (Ford, PI) 7/02/99 - 6/30/04
Doris Duke Charitable Foundation
Molecular Basis of Drug Sensitivity in Upper GI Cancers

California Breast Cancer Research Program (Ford, Co-PI) 7/01/02 – 10/01/03
Genetic Alterations in MRI Screen-Detected Breast Lesions

Burroughs Wellcome Fund New Investigator Award (Ford, PI) 7/01/00-06/20/03
Transcriptional Regulation of DNA Damage Inducible DNA Repair Genes

NIH/NCI RO1 CA83889-03 (Ford, PI) 1/01/00-12/31/02
Mechanism of p53-Dependent DNA Excision Repair

Sidney Kimmel Foundation Scholar Award (Ford, PI) 7/01/99 - 6/30/01
Mechanism of p53 - Dependent DNA Repair

The V Foundation for Cancer Research (Ford, PI) 8/01/99 - 7/31/01
Molecular Determinants of Drug Sensitivity in GI Cancers

NIH/NCI K08 Clinical-Investigator Award (Ford, PI) 9/01/95 – 8/30/99
Role of p53 gene in cellular sensitivity to DNA damage